涉嫌单位行贿罪 信邦制药被检察院提起公诉

Core Viewpoint - Guizhou Xibang Pharmaceutical Co., Ltd. is facing legal challenges due to allegations of corporate bribery, which may negatively impact its profits and is currently under court review [1][2] Group 1: Legal Issues - The company has received a prosecution notice from the People's Procuratorate of Kaiyang County, alleging that it has committed corporate bribery under Article 393 of the Criminal Law of the People's Republic of China [1] - The case is currently in the court trial phase, and the final outcome will depend on the court's judgment [1] - Guizhou Xibang Pharmaceutical's subsidiary, Guizhou Kexin Pharmaceutical Co., Ltd., which is 99.99% owned by Xibang, is also implicated in bribery charges [1] Group 2: Financial Performance - In 2024, the company experienced a decline in both revenue and net profit, with net profit dropping by over 60% year-on-year [2] - For the first three quarters of 2025, the company reported revenue of 4.266 billion yuan, a decrease of 6.55% year-on-year, and a net profit of 152.3 million yuan, down 13.74% year-on-year [2]